preferred or dupilumab for moderate-severe allergic asthma with 1 OCS exacerbation/year Eosinophilic (eos 300 cells/L): Mepolizumab (Nucala, anti-IL5), benralizumab (Fasenra, anti-IL5R), reslizumab (Cinqair IV, anti-IL5), or dupilumab (anti-IL4R/IL-13) Mixed/Broad T2: Dupilumab (atopic dermatitis or EoE comorbidity preferred) or tezepelumab (Tezspire, anti-TSLP efficacy across all phenotypes including T2-low) Aspirin-exacerbated respiratory disease (AERD): Dupilumab preferred
Please scroll down and comment
Previous Slide Next Slide Why c-stores
Chewing tobacco has many other harmful effects on the body that should be considered
The move was a pretty clear reference to Cignetti and how some Indiana fans have referenced the coach during the course of the season
Ideal for the steam scene, the steam robot is perfectly versatile